TipRanks on MSN

Pfizer’s New Study on Drug Interactions: What Investors Need to Know

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. has launched a Phase 1 clinical study titled ‘AN ...

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non ...

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) ...

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, including a product theater presentation highlighting VOQUEZNA ® (vonoprazan) ...
Le Lézard

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences, Inc. will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American ...